REMARKS

Upon entry of the above amendments, 13 claims will be pending (#s 162-174). The new claims do not constitute new matter and find full support, e.g., in the original claims as filed, with the exception that the proviso "and wherein said compound does not comprise sequence LLDICELKLQECARRCN (SEQ ID NO: 208)" has been added to distinguish from the literal scope of the allowed claims in the parent application.

Please kindly direct all telephonic and facsimile correspondence to the undersigned at Ph (858) 485 0513 and Fax: (858) 485 0516.

Respectfully submitted,

Dated: 9/9/03

By:

Edward O. Kreusser
BioTechnology Law Group

Reg. No. 38,52